{"protocolSection": {"identificationModule": {"nctId": "NCT00368277", "orgStudyIdInfo": {"id": "CSPP100A2344"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly", "officialTitle": "A 36 Week Randomized, Double-blind, Parallel Group, Multi-center, Active-controlled, Optional Titration Study Comparing an Aliskiren-based Regimen to a Ramipril-based Regimen in Patients \u2265 65 Years Old With Systolic Essential Hypertension"}, "statusModule": {"statusVerifiedDate": "2011-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2006-09"}, "primaryCompletionDateStruct": {"date": "2008-02", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-02", "type": "ACTUAL"}, "studyFirstSubmitDate": "2006-08-22", "studyFirstSubmitQcDate": "2006-08-22", "studyFirstPostDateStruct": {"date": "2006-08-24", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-12-14", "resultsFirstSubmitQcDate": "2011-02-28", "resultsFirstPostDateStruct": {"date": "2011-03-25", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-02-28", "lastUpdatePostDateStruct": {"date": "2011-03-25", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "External Affairs", "oldOrganization": "Novartis Pharmaceuticals"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "Evaluate the systolic blood pressure lowering effect of aliskiren 150mg and 300mg compared to ramipril 5mg and 10mg in elderly patients with essential systolic hypertension."}, "conditionsModule": {"conditions": ["Hypertension"], "keywords": ["Systolic hypertension", "hypertension", "aliskiren", "blood pressure", "ramipril", "HTN"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 901, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Aliskiren-based regimen", "type": "EXPERIMENTAL", "description": "Aliskiren 150 mg; aliskiren 300 mg; aliskiren 300mg + hydrochlorothiazide 12.5 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg + amlodipine 10 mg", "interventionNames": ["Drug: Aliskiren", "Drug: Hydrochlorothiazide", "Drug: Amlodipine"]}, {"label": "Ramipril-based regimen", "type": "ACTIVE_COMPARATOR", "description": "Ramipril 5 mg; Ramipril 10 mg; Ramipril 10 mg + hydrochlorothiazide 12.5 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg + amlodipine 10mg", "interventionNames": ["Drug: Ramipril", "Drug: Hydrochlorothiazide", "Drug: Amlodipine"]}], "interventions": [{"type": "DRUG", "name": "Aliskiren", "description": "Aliskiren 150 mg and 300 mg tablets taken orally, once a day in the morning", "armGroupLabels": ["Aliskiren-based regimen"]}, {"type": "DRUG", "name": "Ramipril", "description": "Ramipril 5 mg and 10 mg capsules taken orally, once a day in the morning", "armGroupLabels": ["Ramipril-based regimen"]}, {"type": "DRUG", "name": "Hydrochlorothiazide", "description": "Hydrochlorothiazide 12.5 or 25 mg capsules taken orally, once a day in the morning", "armGroupLabels": ["Aliskiren-based regimen", "Ramipril-based regimen"]}, {"type": "DRUG", "name": "Amlodipine", "description": "Amlodipine 5 mg or 10 mg tablets taken orally, once a day in the morning", "armGroupLabels": ["Aliskiren-based regimen", "Ramipril-based regimen"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Mean Sitting Systolic Blood Pressure to Week 12", "timeFrame": "Baseline and Week 12"}], "secondaryOutcomes": [{"measure": "Percentage of Patients With Cough", "timeFrame": "Weeks 12 and 36"}, {"measure": "Percentage of Patients Achieving Blood Pressure Control at Weeks 12 and 36 Endpoints", "description": "Blood pressure control is defined as a mean sitting blood pressure \\< 140/90 mm Hg", "timeFrame": "Weeks 12 and 36"}, {"measure": "Change From Baseline in the Mean Sitting Diastolic Blood Pressure to Week 36", "timeFrame": "Baseline and week 36"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female outpatients \u2265 65 years old.\n* Patients with essential hypertension with an msSBP \u2265 140 mmHg and \\< 180 mmHg, and msDBP \\< 110 mmHg at Visits 2 and 3. (Visit 201 was deleted by the Administrative Changes document.)\n* Patients must have had a difference in msSBP of \u2264 20 mmHg between Visit 3 and the visit immediately prior to Visit 3.\n* Patients who were eligible and able to participate in the study, and who consented to do so after the purpose and nature of the investigation had been explained to them (written informed consent).\n\nExclusion Criteria:\n\n* History of renal artery stenosis.\n* Known Keith-Wagener grade III or IV hypertensive retinopathy.\n* History of hypertensive encephalopathy.\n* Current diagnosis of heart failure (New York Heart Association Class III-IV).\n* History of transient ischemic cerebral attack or cerebrovascular accident within 6 months.\n* History of myocardial infarction, bypass surgery, or any percutaneous coronary intervention within 6 months.\n* Current unstable angina pectoris. Patients on a stable dose of oral or topical nitrates or beta blockers for angina were acceptable.\n* Concurrent potentially life threatening arrhythmia or symptomatic arrhythmia.\n* Clinically significant valvular heart disease.\n* Concurrent use of any antihypersensitive medications except a stable dose 3 months prior to visit 1 of alpha adrenergic blockers for benign prostatic hypertrophy (e.g., Flomax for BPH), beta blockers for angina, or beta blockers ophthalmic preparations.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "65 Years", "stdAges": ["OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novartis Pharmaceuticals", "city": "East Hanover", "state": "New Jersey", "zip": "07936", "country": "United States", "geoPoint": {"lat": 40.8201, "lon": -74.36487}}]}, "referencesModule": {"references": [{"pmid": "33089502", "type": "DERIVED", "citation": "Wang GM, Li LJ, Tang WL, Wright JM. Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database Syst Rev. 2020 Oct 22;10(10):CD012569. doi: 10.1002/14651858.CD012569.pub2."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Aliskiren Based Treatment Regimen", "description": "Aliskiren 150 mg; aliskiren 300 mg; aliskiren 300mg + hydrochlorothiazide 12.5 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg + amlodipine 10 mg"}, {"id": "FG001", "title": "Ramipril Based Treatment Regimen", "description": "Ramipril 5 mg; Ramipril 10 mg; Ramipril 10 mg + hydrochlorothiazide 12.5 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg + amlodipine 10mg"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "457"}, {"groupId": "FG001", "numSubjects": "444"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "344"}, {"groupId": "FG001", "numSubjects": "336"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "113"}, {"groupId": "FG001", "numSubjects": "108"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "33"}, {"groupId": "FG001", "numSubjects": "49"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Unsatisfactory therapeutic effect", "reasons": [{"groupId": "FG000", "numSubjects": "31"}, {"groupId": "FG001", "numSubjects": "24"}]}, {"type": "Protocol deviation", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Patient withdrew consent", "reasons": [{"groupId": "FG000", "numSubjects": "32"}, {"groupId": "FG001", "numSubjects": "28"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "6"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Aliskiren Based Treatment Regimen", "description": "Aliskiren 150 mg; aliskiren 300 mg; aliskiren 300mg + hydrochlorothiazide 12.5 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg + amlodipine 10 mg"}, {"id": "BG001", "title": "Ramipril Based Treatment Regimen", "description": "Ramipril 5 mg; Ramipril 10 mg; Ramipril 10 mg + hydrochlorothiazide 12.5 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg + amlodipine 10mg"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "457"}, {"groupId": "BG001", "value": "444"}, {"groupId": "BG002", "value": "901"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "72.0", "spread": "5.56"}, {"groupId": "BG001", "value": "72.2", "spread": "5.62"}, {"groupId": "BG002", "value": "72.1", "spread": "5.58"}]}]}]}, {"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "65 - 74 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "312"}, {"groupId": "BG001", "value": "296"}, {"groupId": "BG002", "value": "608"}]}]}, {"title": "75 years and older", "categories": [{"measurements": [{"groupId": "BG000", "value": "145"}, {"groupId": "BG001", "value": "148"}, {"groupId": "BG002", "value": "293"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "235"}, {"groupId": "BG001", "value": "237"}, {"groupId": "BG002", "value": "472"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "222"}, {"groupId": "BG001", "value": "207"}, {"groupId": "BG002", "value": "429"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Mean Sitting Systolic Blood Pressure to Week 12", "populationDescription": "Intent to treat (ITT), Last Observation Carried forward (LOCF)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "Aliskiren Based Treatment Regimen", "description": "Aliskiren 150 mg; aliskiren 300 mg; aliskiren 300mg + hydrochlorothiazide 12.5 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg + amlodipine 10 mg"}, {"id": "OG001", "title": "Ramipril Based Treatment Regimen", "description": "Ramipril 5 mg; Ramipril 10 mg; Ramipril 10 mg + hydrochlorothiazide 12.5 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg + amlodipine 10mg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "451"}, {"groupId": "OG001", "value": "439"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-13.96", "spread": "0.754", "lowerLimit": "-15.15", "upperLimit": "-12.13"}, {"groupId": "OG001", "value": "-11.64", "spread": "0.759", "lowerLimit": "-12.76", "upperLimit": "-9.90"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients With Cough", "populationDescription": "Safety population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "Weeks 12 and 36", "groups": [{"id": "OG000", "title": "Aliskiren Based Treatment Regimen", "description": "Aliskiren 150 mg; aliskiren 300 mg; aliskiren 300mg + hydrochlorothiazide 12.5 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg + amlodipine 10 mg"}, {"id": "OG001", "title": "Ramipril Based Treatment Regimen", "description": "Ramipril 5 mg; Ramipril 10 mg; Ramipril 10 mg + hydrochlorothiazide 12.5 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg + amlodipine 10mg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "452"}, {"groupId": "OG001", "value": "444"}]}], "classes": [{"title": "Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.1", "spread": "0.788"}, {"groupId": "OG001", "value": "9.9", "spread": "0.794"}]}]}, {"title": "Week 36", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.4"}, {"groupId": "OG001", "value": "14.2"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients Achieving Blood Pressure Control at Weeks 12 and 36 Endpoints", "description": "Blood pressure control is defined as a mean sitting blood pressure \\< 140/90 mm Hg", "populationDescription": "intent to treat (ITT), last observation carried forward (LOCF)", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Weeks 12 and 36", "groups": [{"id": "OG000", "title": "Aliskiren Based Treatment Regimen", "description": "Aliskiren 150 mg; aliskiren 300 mg; aliskiren 300mg + hydrochlorothiazide 12.5 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg + amlodipine 10 mg"}, {"id": "OG001", "title": "Ramipril Based Treatment Regimen", "description": "Ramipril 5 mg; Ramipril 10 mg; Ramipril 10 mg + hydrochlorothiazide 12.5 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg + amlodipine 10mg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "451"}, {"groupId": "OG001", "value": "440"}]}], "classes": [{"title": "week 12 endpoint", "categories": [{"measurements": [{"groupId": "OG000", "value": "46.3"}, {"groupId": "OG001", "value": "39.3"}]}]}, {"title": "week 36 endpoint", "categories": [{"measurements": [{"groupId": "OG000", "value": "65.6"}, {"groupId": "OG001", "value": "57.5"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in the Mean Sitting Diastolic Blood Pressure to Week 36", "populationDescription": "Intent to treat (ITT), Last Observation Carried forward (LOCF)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline and week 36", "groups": [{"id": "OG000", "title": "Aliskiren Based Treatment Regimen", "description": "Aliskiren 150 mg; aliskiren 300 mg; aliskiren 300mg + hydrochlorothiazide 12.5 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg + amlodipine 10 mg"}, {"id": "OG001", "title": "Ramipril Based Treatment Regimen", "description": "Ramipril 5 mg; Ramipril 10 mg; Ramipril 10 mg + hydrochlorothiazide 12.5 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg + amlodipine 10mg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "451"}, {"groupId": "OG001", "value": "439"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-8.24", "spread": "0.409"}, {"groupId": "OG001", "value": "-7.02", "spread": "0.411"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "36 weeks", "eventGroups": [{"id": "EG000", "title": "Aliskiren", "description": "Aliskiren based regimen", "seriousNumAffected": 35, "seriousNumAtRisk": 452, "otherNumAffected": 170, "otherNumAtRisk": 452}, {"id": "EG001", "title": "Ramipril", "description": "Ramipril based regimen", "seriousNumAffected": 27, "seriousNumAtRisk": 444, "otherNumAffected": 181, "otherNumAtRisk": 444}], "seriousEvents": [{"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 444}]}, {"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 444}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 444}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 444}]}, {"term": "Cardiac arrest", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 444}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 444}]}, {"term": "Sinus bradycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 444}]}, {"term": "Sinus tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 444}]}, {"term": "Tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 444}]}, {"term": "Trifascicular block", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 444}]}, {"term": "Ventricular tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 444}]}, {"term": "Vertigo", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 444}]}, {"term": "Thyroid mass", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 444}]}, {"term": "Diplopia", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 444}]}, {"term": "Eye movement disorder", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 444}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 444}]}, {"term": "Aphagia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 444}]}, {"term": "Ascites", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 444}]}, {"term": "Colitis ischaemic", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 444}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 444}]}, {"term": "Diverticulum", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 444}]}, {"term": "Gastrointestinal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 444}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 444}]}, {"term": "Pancreatic mass", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 444}]}, {"term": "Pancreatitis acute", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 444}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 444}]}, {"term": "Malaise", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 444}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 444}]}, {"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 444}]}, {"term": "Abdominal abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 444}]}, {"term": "Catheter site infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 444}]}, {"term": "Diverticulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 444}]}, {"term": "Myringitis bullous", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 444}]}, {"term": "Otitis externa", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 444}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 444}]}, {"term": "Sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 444}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 444}]}, {"term": "Ankle fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 444}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 444}]}, {"term": "Hip fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 444}]}, {"term": "Lower limb fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 444}]}, {"term": "Skin laceration", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 444}]}, {"term": "Dehydration", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 444}]}, {"term": "Hyperglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 444}]}, {"term": "Hypokalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 444}]}, {"term": "Costochondritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 444}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 444}]}, {"term": "Basal cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 444}]}, {"term": "Bladder cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 444}]}, {"term": "Breast cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 444}]}, {"term": "Colon cancer stage 0", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 444}]}, {"term": "Glioblastoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 444}]}, {"term": "Head and neck cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 444}]}, {"term": "Malignant melanoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 444}]}, {"term": "Metastatic neoplasm", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 444}]}, {"term": "Ovarian cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 444}]}, {"term": "Pancreatic carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 444}]}, {"term": "Prostate cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 444}]}, {"term": "Squamous cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 444}]}, {"term": "Squamous cell carcinoma of skin", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 444}]}, {"term": "Anoxic encephalopathy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 444}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 444}]}, {"term": "Coma", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 444}]}, {"term": "Convulsion", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 444}]}, {"term": "Hypoaesthesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 444}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 444}]}, {"term": "VIth nerve paralysis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 444}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 444}]}, {"term": "Chronic obstructive pulmonary disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 444}]}, {"term": "Pulmonary embolism", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 444}]}, {"term": "Pulmonary oedema", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 444}]}, {"term": "Deep vein thrombosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 444}]}, {"term": "Femoral arterial stenosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 444}]}, {"term": "Haematoma", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 444}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 444}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 444}]}, {"term": "Intermittent claudication", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 444}]}, {"term": "Malignant hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 444}]}], "otherEvents": [{"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 29, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 22, "numAtRisk": 444}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 28, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 20, "numAtRisk": 444}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 23, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 20, "numAtRisk": 444}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 35, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 28, "numAtRisk": 444}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 17, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 24, "numAtRisk": 444}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 34, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 37, "numAtRisk": 444}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 42, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 40, "numAtRisk": 444}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 19, "numAtRisk": 452}, {"groupId": "EG001", "numAffected": 59, "numAtRisk": 444}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novaris Phamaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M1470", "name": "Essential Hypertension", "relevance": "LOW"}, {"id": "M27583", "name": "Systolic Murmurs", "relevance": "LOW"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "D000006852", "term": "Hydrochlorothiazide"}, {"id": "D000017257", "term": "Ramipril"}, {"id": "C000446481", "term": "Aliskiren"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000049993", "term": "Sodium Chloride Symporter Inhibitors"}, {"id": "D000092502", "term": "Renin Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000000806", "term": "Angiotensin-Converting Enzyme Inhibitors"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M9910", "name": "Hydrochlorothiazide", "asFound": "Prescription", "relevance": "HIGH"}, {"id": "M19553", "name": "Ramipril", "asFound": "Mandibular", "relevance": "HIGH"}, {"id": "M352589", "name": "Aliskiren", "asFound": "Distribution", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M26152", "name": "Sodium Chloride Symporter Inhibitors", "relevance": "LOW"}, {"id": "M2932", "name": "Renin Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M4134", "name": "Angiotensin-Converting Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}